Examples of BPCI Act in a sentence
Specifically, the Biologics Price Competition and Innovation Act of 2009, or the BPCI Act, amended the Public Health Service Act to provide an abbreviated licensure pathway for biological products, or 351(k) application, shown to be biosimilar to, or interchangeable with, an FDA-licensed biological reference product.
On March 23, 2010, the BPCI Act was enacted as part of the Patient Protection and Affordable Care Act (Public Law 111-148).
The BPCI Act amended the PHS Act and other statutes to create an abbreviated licensure pathway in section 351(k) of the PHS Act for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed biological reference product (see sections 7001 through 7003 of the BPCI Act).
The objectives of the BPCI Act are conceptually similar to those of the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) (commonly referred to as the “Hatch-Waxman Amendments”), which established abbreviated pathways for the approval of drug products under section 505(b)(2) and 505(j) of the FD&C Act.
Q.II.1. [This question and answer have been withdrawn and moved to FDA’s draft guidance for industry, New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 2).] Q.
FDA is proposing to amend its regulations to implement certain aspects of the BPCI Act.
The BPCI Act requires that marketing applications for “biological products” needs to be submitted as a biologic licence application, or BLA.
Section 351(k) of the PHS Act (42U.S.C. 262(k)), added by the BPCI Act, sets forth the requirements for a biosimilar product application.
The objectives of the BPCI Act are conceptually similar to those of the Drug Price Competition and Patent Term Restoration Act of 1984 (Pub.
Formalizing these interpretations would reduce regulatory uncertainty introduced by the BPCI Act.